Skip to main content
. 2022 Oct 10;22(2):127–144. doi: 10.1038/s41573-022-00571-8

Fig. 6. p53-based genetic therapies.

Fig. 6

Wild-type p53 (wtp53)-encoding DNA and RNA can be introduced into cancer cells by several approaches, including recombinant viruses and nanoparticles. This drives p53 expression and transcription of wtp53 target genes, resulting in anticancer effects. In TP53-mutated tumours, delivery of CRISPR–Cas9 together with suitable guide RNA (gRNA) might potentially enable base editing, restoring wild-type TP53 sequence.